Primary severe acute respiratory syndrome coronavirus infection limits replication but not lung inflammation upon homologous rechallenge

Journal of Virology

Volumn 86, Issue 8, 2012, Pages 4234-4244

  Clay, Candice ^a,b   Donart, Nathan ^a   Fomukong, Ndingsa ^a   Knight, Jennifer B ^a   Lei, Wanli ^a   Price, Lance ^a   Hahn, Fletcher ^a   Westrienen, Jesse Van ^a   Harrod, Kevin S ^a  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELL ACTIVATION; CELL POPULATION; CHLOROCEBUS; CONTROLLED STUDY; DENDRITIC CELL; DISEASE SEVERITY; IMMUNE RESPONSE; IMMUNOMODULATION; LEUKOCYTE COUNT; LUNG ALVEOLUS MACROPHAGE; NONHUMAN; PERSISTENT INFECTION; PNEUMONIA; PRIMARY INFECTION; PRIORITY JOURNAL; SEVERE ACUTE RESPIRATORY SYNDROME; VIRAL CLEARANCE; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CERCOPITHECUS AETHIOPS; CORONAVIRUS; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LUNG; MACROPHAGE ACTIVATION; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MONOCYTES; PNEUMONIA; SEVERE ACUTE RESPIRATORY SYNDROME; T-LYMPHOCYTES; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION;

ANIMALIA; CERCOPITHECUS AETHIOPS; SARS CORONAVIRUS;

EID: 84861392586     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06791-11     Document Type: Article

References (62)

1. Berry JD, et al. 2004. Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. J. Virol. Methods 120:87-96.
2. Cameron MJ, et al. 2007. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J. Virol. 81:8692-8706.
3. Chen H, et al. 2005. Response of memory CD8+ T cells to severe acute respiratory syndrome (SARS) coronavirus in recovered SARS patients and healthy individuals. J. Immunol. 175:591-598.
4. Chen J, Subbarao K. 2007. The immunobiology of SARS*. Annu. Rev. Immunol. 25:443-472.
5. Chen RF, et al. 2006. Role of vascular cell adhesion molecules and leukocyte apoptosis in the lymphopenia and thrombocytopenia of patients with severe acute respiratory syndrome (SARS). Microbes Infect. 8:122-127.
6. Cheng PK, et al. 2004. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet 363:1699-1700.
7. Cheung CY, et al. 2005. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J. Virol. 79:7819-7826.
8. Chiang SF, Lin TY, Chow KC, Chiou SH. 2010. SARS spike protein induces phenotypic conversion of human B cells to macrophage-like cells. Mol. Immunol. 47:2575-2586.
9. Chow KC, Hsiao CH, Lin TY, Chen CL, Chiou SH. 2004. Detection of severe acute respiratory syndrome-associated coronavirus in pneumocytes of the lung. Am. J. Clin. Pathol. 121:574-580.
10. Chu YK, et al. 2008. The SARS-CoV ferret model in an infectionchallenge study. Virology 374:151-163.
11. Clay CC, et al. 2004. Chemokine networks and in vivo T-lymphocyte trafficking in nonhuman primates. J. Immunol. Methods 293:23-42.
12. de Lang A, et al. 2007. Functional genomics highlights differential induction of antiviral pathways in the lungs of SARS-CoV-infected macaques. PLoS Pathog. 3:e112.
13. Devaraj SG, et al. 2007. Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J. Biol. Chem. 282:32208-32221.
14. Drosten C, et al. 2004. Evaluation of advanced reverse transcription-PCR assays and an alternative PCR target region for detection of severe acute respiratory syndrome-associated coronavirus. J. Clin. Microbiol. 42: 2043-2047.
15. Frieman M, et al. 2007. Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J. Virol. 81:9812-9824.
16. Goulding J, et al. 2007. Respiratory infections: do we ever recover? Proc. Am. Thorac. Soc. 4:618-625.
17. Haagmans BL, Osterhaus AD. 2006. Coronaviruses and their therapy. Antiviral Res. 71:397-403.
18. He Y, et al. 2004. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem. Biophys. Res. Commun. 324:773-781.
19. Hsueh PR, Huang LM, Chen PJ, Kao CL, Yang PC. 2004. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin. Microbiol. Infect. 10:1062-1066.
20. Hui DS, et al. 2005. The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors. Chest 128:2247-2261.
21. Kopecky-Bromberg SA, Martinez-Sobrido L, Frieman M, Baric RA, Palese P. 2007. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J. Virol. 81:548-557.
22. Kuiken T, et al. 2003. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362:263-270.
23. Lau SK, et al. 2005. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl. Acad. Sci. U. S. A. 102:14040-14045.
24. Law HK, et al. 2005. Chemokine up-regulation in SARS-coronavirusinfected, monocyte-derived human dendritic cells. Blood 106:2366-2374.
25. Li C, Xu X. 2010. Host immune response to SARS coronavirus in humans. In Lal SK (ed), Molecular biology of the SARS-coronavirus, vol 1. Springer-Verlag, New York, NY.
26. Li W, et al. 2005. Bats are natural reservoirs of SARS-like coronaviruses. Science 310:676-679.
27. Martina BE, et al. 2003. Virology: SARS virus infection of cats and ferrets. Nature 425:915.
28. Marzi A, et al. 2004. DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J. Virol. 78:12090-12095.
29. McAuliffe J, et al. 2004. Replication of SARS coronavirus administered into the respiratory tract of African green, rhesus and cynomolgus monkeys. Virology 330:8-15.
30. Narayanan K, et al. 2008. Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J. Virol. 82:4471-4479.
31. Ong KC, et al. 2004. Pulmonary function and exercise capacity in survivors of severe acute respiratory syndrome. Eur. Respir. J. 24:436-442.
32. Peiris JS, et al. 2003. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361:1767-1772.
33. Peiris JS, et al. 2003. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361:1319-1325.
34. Peiris JS, Porterfield JS. 1979. Antibody-mediated enhancement of flavivirus replication in macrophage-like cell lines. Nature 282:509-511.
35. Peiris JS, Yuen KY, Osterhaus AD, Stohr K. 2003. The severe acute respiratory syndrome. N. Engl. J. Med. 349:2431-2441.
36. Peng H, et al. 2006. Human memory T cell responses to SARS-CoV E protein. Microbes Infect. 8:2424-2431.
37. Peng H, et al. 2006. Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients. Virology 351:466-475.
38. Perlman S, Dandekar AA. 2005. Immunopathogenesis of coronavirus infections: implications for SARS. Nat. Rev. Immunol. 5:917-927.
39. Pollard AM, Lipscomb MF. 1990. Characterization of murine lung dendritic cells: similarities to Langerhans cells and thymic dendritic cells. J. Exp. Med. 172:159-167.
40. Roberts A, et al. 2007. Animal models and vaccines for SARS-CoV infection. Virus Res. 133:20-32.
41. Roberts A, et al. 2005. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J. Virol. 79:503-511.
42. Rockx B, et al. 2008. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J. Virol. 82:3220-3235.
43. Reference deleted.
44. Spiegel M, Schneider K, Weber F, Weidmann M, Hufert FT. 2006. Interaction of severe acute respiratory syndrome-associated coronavirus with dendritic cells. J. Gen. Virol. 87:1953-1960.
45. Sullivan NJ. 2001. Antibody-mediated enhancement of viral disease. Curr. Top. Microbiol. Immunol. 260:145-169.
46. Temperton NJ, et al. 2005. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg. Infect. Dis. 11: 411-416.
47. ter Meulen J, et al. 2004. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 363:2139-2141.
48. Tseng CT, Perrone LA, Zhu H, Makino S, Peters CJ. 2005. Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection. J. Immunol. 174: 7977-7985.
49. Warnes GR, et al. 2009. gplots: various R programming tools for plotting data. The Comprehensive R Archive Network. http://cran.r-project.org/package=gplots.
50. Weingartl H, et al. 2004. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J. Virol. 78:12672-12676.
51. WHO. 2003. The world health report 2003-shaping the future. World Health Organization, Geneva, Switzerland.
52. Wong RS, et al. 2003. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ 326:1358-1362.
53. Yang L, et al. 2007. Persistent memory CD4+and CD8+T-cell responses in recovered severe acute respiratory syndrome (SARS) patients to SARS coronavirus M antigen. J. Gen. Virol. 88:2740-2748.
54. Yang LT, et al. 2006. Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients. Clin. Immunol. 120:171-178.
55. Yang Y, et al. 2005. Bcl-xL inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the absence of growth factors. Biochem. J. 392:135-143.
56. Yang ZY, et al. 2004. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J. Virol. 78:5642-5650.
57. Yang ZY, et al. 2005. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc. Natl. Acad. Sci. U. S. A. 102:797-801.
58. Yasui F, et al. 2008. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J. Immunol. 181:6337-6348.
59. Yilla M, et al. 2005. SARS-coronavirus replication in human peripheral monocytes/macrophages. Virus Res. 107:93-101.
60. Yoshikawa T, Hill T, Li K, Peters CJ, Tseng CT. 2009. Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. J. Virol. 83:3039-3048.
61. Zhao J, Van Rooijen N, Perlman S. 2009. Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice. PLoS Pathog. 5:e1000636.
62. Zhu Z, et al. 2007. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc. Natl. Acad. Sci. U. S. A. 104:12123-12128.